CoChat

An enolase inhibitor for the targeted treatment of ENO1-deleted cancers

Open access
Lin, Yu-Hsi, Satani, Nikunj, Hammoudi, Naima, Yan, Victoria C., Barekatain, Yasaman, Khadka, Sunada, Ackroyd, Jeffrey J., Georgiou, Dimitra K., Pham, Cong-Dat, Arthur, Kenisha, Maxwell, David, Peng, Zhenghong, Leonard, Paul G., Czako, Barbara, Pisaneschi, Federica, Mandal, Pijus, Sun, Yuting, Zielinski, Rafal, Pando, Susana Castro, Wang, Xiaobo, Tran, Theresa, Xu, Quanyu, Wu, Qi, Jiang, Yongying, Kang, Zhijun, Asara, John M., Priebe, Waldemar, Bornmann, William, Marszalek, Joseph R., DePinho, Ronald A., Muller, Florian L. · 2020 · Nature Metabolism
Cited by 91

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Inhibiting glycolysis remains an aspirational approach for the treatment of cancer. We have previously identified a subset of cancers harbouring homozygous deletion of the glycolytic enzyme enolase (ENO1) that have exceptional sensitivity to inhibition of its redundant paralogue, ENO2, through a therapeutic strategy known as collateral lethality. Here, we show that a small-molecule enolase inhibitor, POMHEX, can selectively kill ENO1-deleted glioma cells at low-nanomolar concentrations and eradicate intracranial orthotopic ENO1-deleted tumours in mice at doses well-tolerated in non-human primates. Our data provide an in vivo proof of principle of the power of collateral lethality in precision oncology and demonstrate the utility of POMHEX for glycolysis inhibition with potential use across a range of therapeutic settings. Oncogenic transformation can render cancer cells dependent on aberrant expression of glycolytic enzyme isoforms. Lin et al. describe a novel enolase inhibitor, POMHEX, that can selectively kill ENO1-deleted glioblastomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42255-020-00313-3

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 91

Metadata

Authors
Lin, Y.-H., Satani, N., Hammoudi, N., Yan, V. C., Barekatain, Y., Khadka, S., Ackroyd, J. J., Georgiou, D. K., Pham, C.-D., Arthur, K., Maxwell, D., Peng, Z., Leonard, P. G., Czako, B., Pisaneschi, F., Mandal, P., Sun, Y., Zielinski, R., Pando, S. C., Wang, X., Tran, T., Xu, Q., Wu, Q., Jiang, Y., Kang, Z., Asara, J. M., Priebe, W., Bornmann, W., Marszalek, J. R., DePinho, R. A., & Muller, F. L.
Venue
Nature Metabolism
Published
2020-11-23
Volume
2
Issue
12
Pages
1413-1426
ISSN
2522-5812 (ISSN-L)
OpenAlex
W3110472159
Cited by
91
References
4
FWCI
3.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. https://app.cochat.ai/papers/10.1038/s42255-020-00313-3
The paper
Lin, Y.-H., Satani, N., Hammoudi, N., Yan, V. C., Barekatain, Y., Khadka, S., Ackroyd, J. J., Georgiou, D. K., Pham, C.-D., Arthur, K., Maxwell, D., Peng, Z., Leonard, P. G., Czako, B., Pisaneschi, F., Mandal, P., Sun, Y., Zielinski, R., Pando, S. C., . . . Muller, F. L. (2020). An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nature Metabolism. https://doi.org/10.1038/s42255-020-00313-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.